UNITED LAB (03933) releases interim results, with a net profit attributable to shareholders of HK$1.894 billion, an increase of 27% year-on-year.

UNITED LAB (03933) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 7.519 billion, an increase of 4.8% compared to the same period last year. The profit attributable to owners of the company was RMB 1.894 billion, a 27% increase, with basic earnings per share of 104.26 cents. The company plans to distribute an interim dividend of 16 cents per share. During the period, the revenue of the divisions for intermediates, active pharmaceutical ingredients (APIs), and formulations (including inter-division sales) were RMB 2.304 billion, RMB 2.999 billion, and RMB 3.9785 billion, respectively. This represents a decrease of 25.2%, 23.4%, and an increase of 65.9% compared to the same period last year. The divisional profits for intermediates, APIs, and formulations were RMB 634.6 million, RMB 250.6 million, and RMB 1.5056 billion, respectively. This shows a decrease of 40.6%, 52.0%, and an increase of 524.2% compared to the same period last year.